NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Dates by Range 2000 and later Remove constraint Dates by Range: 2000 and later

Search Results

5921. Placebos and blinding in randomized controlled cancer clinical trials for drug and biological products

5922. Factors to consider when making benefit-risk determinations in medical device premarket approval and de novo classifications: guidance for industry and Food and Drug Administration staff

5923. Consideration of uncertainty in making benefit-risk determinations in medical device premarket approvals, de novo classifications, and humanitarian device exemptions: guidance for industry and Food and Drug Administration staff

5924. Evaluation of internal standard responses during chromatographic bioanalysis: questions and answers

5925. Drugs for treatment of partial onset seizures: full extrapolation of efficacy from adults to pediatric patients 2 years of age and older

5926. Humanitarian device exemption (HDE) program: guidance for industry and Food and Drug Administration staff

5928. Citizen petitions and petitions for stay of action subject to section 505(q) of the Federal Food, Drug, and Cosmetic Act

5929. Wholesale distributor verification requirement for saleable returned drug product: compliance policy

5930. Amyotrophic lateral sclerosis: developing drugs for treatment